ABSTRACT
The presented clinical observation reflects the difficulties of differential diagnosis of progressive kidney damage in a patient with sarcoidosis who has undergone a new coronavirus infection. The differential circle included interstitial nephritis as an exacerbation of the underlying disease, acute drug-induced kidney injury, acute glomerulonephritis. Nephrobiopsy confirmed the diagnosis of acute sarcoid tubulointerstitial nephritis with acute tubular necrosis. Timely administration of corticosteroids led to the control of the sarcoidosis process, restoration of kidney function.
Subject(s)
COVID-19 , Nephritis, Interstitial , Sarcoidosis , Humans , COVID-19/diagnosis , Nephritis, Interstitial/diagnosis , Nephritis, Interstitial/drug therapy , Nephritis, Interstitial/etiology , Sarcoidosis/complications , Sarcoidosis/diagnosis , Sarcoidosis/drug therapy , Adrenal Cortex Hormones/therapeutic use , Kidney/pathologyABSTRACT
Patients with refractory cardiac sarcoidosis (CS) take a high dose of corticosteroid and immunosuppressive agents. During the pandemic outbreak of severe acute respiratory syndrome coronavirus 2, appropriate treatment of corticosteroids or immunosuppressive agents in CS patients with coronavirus disease 2019 (COVID-19) is unknown. Here, the woman with refractory CS receiving maintenance therapy with 15 mg of prednisolone daily and 10 mg of methotrexate weekly was emergently admitted to our hospital because of COVID-19. This case was successfully treated by the intravenous administration of dexamethasone 6 mg/day instead of prednisolone and interruption of methotrexate without resulting in recurrent life-threatening ventricular lethal arrhythmias or obvious sarcoidosis flare-ups. She started taking prednisolone and methotrexate at the maintenance dose immediately and at 2 weeks after discharge, respectively. Although the optimal regimen of immunosuppressive agents during COVID-19 is under intense debate, this report might provide an effective treatment strategy for CS patients with COVID-19.
Subject(s)
COVID-19 , Pharmaceutical Preparations , Sarcoidosis , Female , Humans , Immunosuppressive Agents , SARS-CoV-2 , Sarcoidosis/diagnosis , Sarcoidosis/drug therapyABSTRACT
PURPOSE OF REVIEW: Patients with sarcoidosis may be at higher risk of coronavirus disease-19 (COVID-19) as over 90% of the patients have pulmonary involvement and many are treated with immunosuppressive agents. This review will summarize the current literature regarding sarcoidosis and COVID-19, with a particular focus on susceptibility, clinical outcomes, management, and approach to vaccination. RECENT FINDINGS: Data about COVID-19 and sarcoidosis include a number of case series and reports, cohort studies, and registries. Literature is not conclusive whether patients with sarcoidosis have increased susceptibility to COVID-19. Patients with moderate to severe impaired pulmonary function may be at increased risk of adverse outcomes and mortality. Whether immunosuppressive medication increases risk of COVID-19 severity or affects vaccination response is not yet clear. Novel approaches, such as telemedicine and home monitoring programs, are promising to ensure continuity of care for patients with sarcoidosis during the COVID-19 pandemic. SUMMARY: Current evidence about the risk and clinical outcomes of COVID-19 infection in patient with sarcoidosis, is mainly extrapolated from other immune-mediated diseases. Hence, further research that focuses on the sarcoidosis population is warranted.
Subject(s)
COVID-19 , Sarcoidosis , Telemedicine , Humans , Pandemics , SARS-CoV-2 , Sarcoidosis/drug therapy , Sarcoidosis/epidemiologySubject(s)
Autoimmune Diseases/drug therapy , COVID-19/therapy , Immunosuppressive Agents/therapeutic use , Adolescent , Adult , Aged , Aged, 80 and over , Anti-Bacterial Agents/therapeutic use , Antibodies, Monoclonal, Humanized/therapeutic use , Antirheumatic Agents/therapeutic use , Arthritis, Rheumatoid/complications , Arthritis, Rheumatoid/drug therapy , Autoimmune Diseases/complications , Azithromycin/therapeutic use , Biological Products/therapeutic use , COVID-19/complications , COVID-19/mortality , Enzyme Inhibitors/therapeutic use , Female , Glucocorticoids/therapeutic use , Hospitalization , Humans , Hydroxychloroquine/therapeutic use , Immunomodulation , Inflammatory Bowel Diseases/complications , Inflammatory Bowel Diseases/drug therapy , Intensive Care Units , Janus Kinase Inhibitors/therapeutic use , Male , Middle Aged , Respiration, Artificial , SARS-CoV-2 , Sarcoidosis/complications , Sarcoidosis/drug therapy , Surveys and Questionnaires , Tumor Necrosis Factor Inhibitors/therapeutic use , Young Adult , COVID-19 Drug TreatmentABSTRACT
BACKGROUND: Since the World Health Organization declared a global pandemic due to the novel coronavirus disease2019, there have been targeted efforts to establish management modalities. Hydroxychloroquine has been suggested as a possible treatment; however, it is associated with multiple adverse reactions. We report a rare case of a patient with acute generalized exanthematous pustulosis with Stevens-Johnson syndrome due to hydroxychloroquine. Acute generalized exanthematous pustulosis is characterized by acute onset of a generalized rash that is pustular and erosive in nature, affecting limbs; trunk; face; and, less often, mucosal membranes. Although rare, it is important to be mindful of this side effect because the diagnosis is often delayed, and the disease has the potential to be life-threatening. CASE PRESENTATION: A 68-year-old American woman presented to our hospital with a painful, rapidly spreading rash. Its morphologic features included erythema multiforme-like lesions with extensive skin sloughing in various regions of the head, neck, and trunk and mucosal involvement. Her Nikolsky sign was negative, and she had no evidence of lesions on areas of skin trauma. Four weeks prior, she had been initiated on hydroxychloroquine for a presumed diagnosis of cutaneous sarcoidosis. Three punch biopsies of the head and neck area revealed subcorneal pustules consistent with acute generalized exanthematous pustulosis. Treatment began with high doses of methylprednisolone, leading to only minimal improvement of existing areas and ongoing spread to new areas. Treatment with intravenous immunoglobulin was initiated, at which point disease stability was achieved. The patient's rash ultimately resolved, as did her cutaneous pain and pruritus. CONCLUSIONS: Among many potential adverse reactions involving hydroxychloroquine, cutaneous side effects are varied and can lead to significant morbidity or even death. The drug is currently being investigated in a multitude of trials for coronavirus disease2019 treatment, prevention, and prophylaxis after exposure to severe acute respiratory syndrome coronavirus 2. Acute generalized exanthematous pustulosis is a rare side effect of hydroxychloroquine, and even fewer cases demonstrate histologic evidence of acute generalized exanthematous pustulosis while clinically presenting with Stevens-Johnson syndrome. Patients who develop Stevens-Johnson syndrome/toxic epidermal necrolysis require best supportive care with aggressive fluid and electrolyte replacement and prevention of further breakdown of the skin barrier. With the potential of widespread hydroxychloroquine use, it is important that providers be aware of its potential severe adverse drug reactions.
Subject(s)
Acute Generalized Exanthematous Pustulosis , Coronavirus Infections/epidemiology , Hydroxychloroquine , Immunoglobulins, Intravenous/administration & dosage , Methylprednisolone/administration & dosage , Pneumonia, Viral/epidemiology , Sarcoidosis/drug therapy , Stevens-Johnson Syndrome , Acute Generalized Exanthematous Pustulosis/diagnosis , Acute Generalized Exanthematous Pustulosis/etiology , Acute Generalized Exanthematous Pustulosis/physiopathology , Acute Generalized Exanthematous Pustulosis/therapy , Aged , Antimalarials/administration & dosage , Antimalarials/adverse effects , Biopsy/methods , COVID-19 , Female , Humans , Hydroxychloroquine/administration & dosage , Hydroxychloroquine/adverse effects , Immunologic Factors , Pandemics , Skin/pathology , Skin Diseases/drug therapy , Stevens-Johnson Syndrome/diagnosis , Stevens-Johnson Syndrome/etiology , Stevens-Johnson Syndrome/physiopathology , Stevens-Johnson Syndrome/therapy , Treatment OutcomeSubject(s)
COVID-19 , Sarcoidosis , Humans , Glucocorticoids/therapeutic use , Sarcoidosis/complications , Sarcoidosis/drug therapy , RecurrenceSubject(s)
COVID-19 , Sarcoidosis , Humans , Glucocorticoids/therapeutic use , Sarcoidosis/complications , Sarcoidosis/drug therapy , RecurrenceABSTRACT
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and mainly affects the lungs. Sarcoidosis is an autoinflammatory disease characterized by the diffusion of granulomas in the lungs and other organs. Here, we discuss how the two diseases might involve some common mechanistic cellular pathways around the regulation of autophagy.